Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL

Enrollment

148

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

March 31, 2005

Conditions

Psoriasis

Interventions

DRUG

adalimumab

OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded 40 mg eow through Week 48, withdrawal and observation for 360 days after last dose

DRUG

placebo for adalimumab

OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded placebo eow through Week 48, withdrawal and observation for 360 days after last dose